The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma

Oral Oncol. 2020 Sep:108:104935. doi: 10.1016/j.oraloncology.2020.104935. Epub 2020 Aug 10.

Authors

Jong Chul Park¹, Julia Durbeck², Karim Boudadi³, Won Jin Ho³, Hyunseok Kang⁴

Affiliations

¹ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
² Massachusetts Eye and Ear, Boston, MA, USA.
³ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
⁴ University of California, San Francisco, San Francisco, CA, USA. Electronic address: Hyunseok.Kang@ucsf.edu.

PMID: 32792211
DOI: 10.1016/j.oraloncology.2020.104935

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Female
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use*
Male
Middle Aged
Nasopharyngeal Carcinoma / drug therapy*
Young Adult

Substances

Immune Checkpoint Inhibitors